MoonLake Immunotherapeutics (MLTX)
Nasdaq: MLTX · Pharmaceutical Preparations · Zug, CH · filing with the SEC since 2020
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Feb 25, 2026 | Feb 26, 2025 | Feb 29, 2024 | Mar 20, 2023 | Feb 17, 2022 | Mar 31, 2021 |
| Research and development | 202,862,000 | 112,771,000r | 31,802,000r | 42,048,954 | · | · |
| General and administrative | 41,972,000 | 30,320,000r | 22,321,000r | 23,012,463 | 4,570,345 | · |
| Total operating expenses | 244,834,000 | 143,091,000r | 54,123,000r | 65,061,417 | · | · |
| Operating income | -244,834,000 | -143,091,000r | -54,123,000r | -65,061,417 | -4,570,345 | · |
| Interest expense | 7,248,000 | 0 | 0 | · | · | · |
| Interest and investment income | · | · | · | · | 27,691 | · |
| Other income (expense), net | · | · | · | 591,732 | · | · |
| Total non-operating income (expense) | · | · | · | · | 27,691 | · |
| Income before income taxes | -229,710,000 | -120,962,000r | -43,985,000r | -64,469,685 | · | · |
| Income tax expense | 611,000 | 282,000r | 94,000r | 36,366 | · | · |
| Net income including non-controlling interests | -230,321,000 | -121,244,000r | -44,079,000r | -64,506,051 | · | · |
| Net income to non-controlling interests | -3,003,000 | -2,308,000r | -8,072,000r | -14,532,802 | -4,542,654 | · |
| Net income | -227,318,000 | -118,936,000r | -36,007,000r | -49,973,249 | -4,542,654 | · |
| Earnings per share, basic | -3.53 | -1.89 | -0.73 | -1.70 | · | · |
| Earnings per share, diluted | -3.53 | -1.89 | -0.73 | -1.70 | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -0.31 | · |
| Weighted average shares, basic | 64,463,889 | 62,870,237 | 49,122,534 | 29,361,353 | · | · |
| Weighted average shares, diluted | 64,463,889 | 62,870,237 | 49,122,534 | 29,361,353 | 360,000,000 | · |
| Weighted average shares, basic and diluted | · | · | · | · | 11,930,000 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income to non-controlling interests the share that belongs to minority holders
us-gaap:NetIncomeLossAttributableToNoncontrollingInterestNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted